Human IgG antibody Laboratories manufactures the spike team s2 ep26 ita reagents distributed by Genprice. The Spike Team S2 Ep26 Ita reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike S2. Other Spike products are available in stock. Specificity: Spike Category: Team Group: S2 Ep26
MERS-CoV Spike protein S2 (aa 726-1296) [His] |
|||
DAG-H10296 | Creative Diagnostics | 20µg | EUR 868.8 |
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
|||
9123-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
|||
9123-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10] |
|||
PM-9428-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10] |
|||
PM-9428-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [5E6] |
|||
PM-9429-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [5E6] |
|||
PM-9429-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A6] |
|||
SD9785-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A6] |
|||
SD9785-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1B8] |
|||
SD9787-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1B8] |
|||
SD9787-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1G5] |
|||
SD9789-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1G5] |
|||
SD9789-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A9] |
|||
SD9791-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A9] |
|||
SD9791-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
Spike Trimer (S1+S2), His-tag (SARS-CoV-2) |
|||
100728-1 | BPS Bioscience | 100 µg | EUR 350 |
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa. |
Spike Trimer (S1+S2), His-tag (SARS-CoV-2) |
|||
100728-2 | BPS Bioscience | 1 mg | EUR 2995 |
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa. |